From blood-based diagnostics and durable disease-modifying therapy in Alzheimer’s disease to age-dependent cardiovascular protection with GLP-1 and SGLT2 therapies, this episode captures the most practice-changing advances of 2025. We unpack 10 high-impact updates, including expanded SGLT2 use across the full spectrum of chronic kidney disease, CDC-endorsed twice-yearly injectable HIV prevention, phenotype-driven biologics in COPD, and long-awaited survival gains in small cell lung cancer redefining frontline and relapsed care. Together, these shifts signal a decisive move toward earlier intervention, precision treatment, and trajectory-altering outcomes across major disease states.